The 21-acre site is home to 2 Washington State Liquor Control Board (WSLCB) approved commercial cannabis gardens. They operate under independent Tier 2 and Tier 3, I-502 Outdoor Producer Licenses. The Tier 2 garden is approved for 10,000 sq ft of canopy, the Tier 3 garden is approved for 30,000 sq ft of canopy.

The strains planted are: Green Ribbon, Toxic Green, Kimbo Kush, Purple Diesel, Cookie Puss, Cookie Monster, Blue Dream, Dr Who, Girl Scout Cookie, Gorilla Glue, Gelato, Ogre, Rosaberry, Dutch Treat, Blood Orange, Pineapple Kush, White LSD, GOD, Permafrost, Short Bread and Mendo Purps

Drone footage and new images will be available at www.marapharm.com under Washington Projects on August 6th, 2018.

Each license and garden must follow the stringent rules set forth by I-502 such as; security, fencing, traceability, employee qualifications and training, destruction of waste, transportation of product, testing, in-depth operation description, products used and soils.

Leading the team of both gardens, is Ian Dykstra, a passionate grower with extensive experience in cannabis cultivation. Ian manages the day-to-day operations of both gardens to ensure maximum efficiency, productivity and quality of the 40,000 sq ft canopy. Working closely with Ian are a team of seasoned cannaculturists.

Ian reports in the last week of May the team planted both gardens, with a culmination of 22 hybrid strains. The Tier 2 garden was planted with 2,160 plants, the Tier 3 garden was planted with 4,860 plants. The 7,020 plants are vibrant, healthy and varying in heights. "The season began with brisk temperatures, but June and July have seen ideal growing conditions with daily averages of 86F and lows of 53F, and the extended forecast looks great. During the next 6 to 8 weeks we will see significant growth."

The initiation to flower using light deprivation is currently underway. Light deprivation, aka light dep, is the process of forcing plants to flower with sunlight in a time of year that is not normally the flowering period of the sun's natural lighting cycle. Similar to controlling the light cycle with a grow light by turning it on and off with a timer, farmers can control the budding cycle by blocking the sunlight, making the plants think it's time to flower. Ian just recently won "Best Light Dep Flower - THC" at the first inaugural 2018 Sun Cup.

Working in synergy with Marapharm`s tenant, Alphapheno, the goal is to process the sun-grown cannabis product at the licenced facility located in Lynden, Washington.

ABOUT MARAPHARM VENTURES INC.

www.marapharm.com

Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.

SOCIAL MEDIA:

Facebook:

facebook.com/marapharm

Twitter: twitter.com/marapharm Web

STOCK EXCHANGES:

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQX, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.

Neither the CSE, the FSE nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.

MARIJUANA INDUSTRY INVOLVEMENT:

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.

Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm's ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm's business is conducted in a manner consistent with state law and is in compliance with licensing requirements.

Copies of licenses are posted on Marapharm's website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.

FORWARD - LOOKING STATEMENTS:

Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

SOURCE Marapharm Ventures Inc.

For further information: www.marapharm.com or Linda Sampson, CEO 778-583-4476 email [email protected]

Related Links

http://www.marapharm.com/

